INVESTINGImmunomedics Gets Double-Downgrade to Sell From Goldman SachsBy Rob LenihanApr 3, 2020 11:30 AM EDT
PRESS RELEASESShareholder Alert: Robbins LLP Reminds Investors Shareholder Class Action Against Immunomedics, Inc. (IMMU) Survives Motion To DismissBy Business WireJun 24, 2020 6:01 PM EDT
INVESTINGImmunomedics Gets Double-Downgrade to Sell From Goldman SachsBy Rob LenihanApr 3, 2020 11:30 AM EDT
PRESS RELEASESImmunomedics To Report Results For The Fourth Quarter And Full Year 2019 And Host Conference Call And Webcast On February 27, 2020By GlobeNewswireFeb 20, 2020 8:00 AM EST
PRESS RELEASESImmunomedics Appoints Dr. Loretta Itri Chief Medical OfficerBy GlobeNewswireFeb 14, 2020 8:00 AM EST
PRESS RELEASESImmunomedics To Participate In Guggenheim Healthcare Talks | Oncology DayBy GlobeNewswireFeb 6, 2020 8:00 AM EST
STOCKSSeattle Genetics Climbs on Positive Trial Results for Bladder Cancer TreatmentBy Tony OwusuSep 30, 2019 1:15 PM EDT
STOCKSImmunomedics Stock Drops After Bladder-Cancer-Drug Results DisappointBy Tony OwusuSep 30, 2019 12:33 PM EDT
OPINIONTuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?By Brian SozziMar 20, 2018 4:43 PM EDT
STOCKS15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesBy Kinsey GrantMar 20, 2018 2:58 PM EDT
MERGERS AND ACQUISITIONSImmunomedics, Seattle Genetics Scrap License DealBy Armie Margaret LeeMay 5, 2017 4:32 PM EDT
HEALTHBiotech Movers: Immunomedics Shares Jump After License Pact With Seattle Genetics Is TerminatedBy Armie Margaret LeeMay 5, 2017 10:42 AM EDT
HEALTHBiotech Premarket Movers: Arena, Immunomedics, AralezBy Armie Margaret LeeMar 15, 2017 9:32 AM EDT
STOCKSImmunomedics Soars on Injunction Against Seattle Genetics DealBy Alicia McElhaneyMar 9, 2017 1:33 PM EST
STOCKSActivist Investor Wins Control of Immunomedics Board Following Shareholder VoteBy Adam FeuersteinMar 3, 2017 12:21 PM EST
VIDEOActivist Investor to Block Partnership of Immunomedics and Seattle GeneticsBy TheStreet StaffFeb 14, 2017 12:33 PM EST
STOCKSActivist investor seeks legal block of Immunomedics cancer drug partnership with Seattle GeneticsBy Adam FeuersteinFeb 14, 2017 10:56 AM EST
JIM CRAMERChesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning RoundBy Scott RuttFeb 14, 2017 6:14 AM EST
JIM CRAMERWhy These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' RecapBy Scott RuttFeb 14, 2017 6:08 AM EST
STOCKSBiotech premarket movers: Sage Therapeutics, Immunomedics, Myriad GeneticsBy Armie Margaret LeeFeb 13, 2017 9:24 AM EST
